JPH09505559A - 万能dr−結合性ペプチドを用いる免疫応答の改変 - Google Patents
万能dr−結合性ペプチドを用いる免疫応答の改変Info
- Publication number
- JPH09505559A JPH09505559A JP7509323A JP50932395A JPH09505559A JP H09505559 A JPH09505559 A JP H09505559A JP 7509323 A JP7509323 A JP 7509323A JP 50932395 A JP50932395 A JP 50932395A JP H09505559 A JPH09505559 A JP H09505559A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- peptides
- ctl
- binding
- alanine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.2個のD−アミノ酸及び11個のL−アミノ酸より成るペプチドを含んで成 る組成物であって、ここで前記ペプチドはアミノ末端からカルボキシ末端の方向 で式R1−R2−R3−R4−R5を有し、ここで: R1はアラニン又はリジンが後続するD−アミノ酸であり; R2はシクロヘキシルアラニン、チロシン及びフェニルアラニンより成る群か ら選ばれ; R3は3又は4個のアミノ酸であり、ここで各アミノ酸は独立してアラニン、 イソロイシン、セリン及びバリンより成る群から選ばれ; R4はスレオニン−ロイシン−リジン、ロイシン−スレオニン及びトリプトフ ァン−スレオニン−ロイシン−リジンより成る群から選ばれ;そして R5はD−アミノ酸が後続する2又は4個のアミノ酸であり、ここでこの2又 は4個のアミノ酸はそれぞれ独立してアラニン、セリン及びバリンより成る群か ら選ばれる; 組成物。 2.R1がアラニン又はリジンの後続するD−アラニンであり; R2がシクロヘキシルアラニン又はフェニルアラニンであり; R3が3又は4個のアミノ酸であり、ここでこの3又は4個のアミノ酸はそれ ぞれアラニン、イソロイシン及びバリンより成る群から選ばれ;そして R5がD−アラニンが後続する2又は4個のアラニンである; 請求項1記載の組成物。 3.前記ペプチドがaAXAAAKTAAAAa,aAXAAAATLKAAa,aAXVAAATLK AAa,aAXIAAATLKAAa,aKXVAAWTLKAAa及びaKFVAAWTLKAAa(ここでaはD−アラニ ン、Aはアラニン、Xはシクロヘキシルアラニン、Kはリジン、Tはスレオニン 、Lはロイシン、Vはバリン、Iはイソロイシン、WはトリプトファンそしてF はフェニルアラニンである)より成る群から選ばれる、請求項2記載の組成物。 4.薬理学的に許容される担体及び請求項1記載のペプチドを含んで成る薬理 組成物。 5.CTL誘導性ペプチド及びTヘルパーペプチドを含んで成る組成物であって 、このTヘルパーペプチドが請求項1記載のペプチドである、組成物。 6.前記CTL誘導性ペプチドがアセチル化、パルミチル化又は脂肪酸によりア シル化されている、請求項5記載の組成物。 7.前記CTL誘導性ペプチドが前記Tヘルパーペプチドに連結されてCTL/Tヘ ルパーペプチドコンジュゲートを形成している、請求項5記載の組成物。 8.前記CTL/Lヘルパーペプチドが担体に連結されている、請求項7記載の 組成物。 9.前記CTL誘導性ペプチドがスペーサー分子によって前記Tヘルパーペプチ ドに連結されている、請求項6記載の組成物。 10.前記スペーサーがAla-Ala-Alaである、請求項9記載の組成物。 11.患者のT細胞の活性化を阻害する方法であって、この患者に、薬理学的に 許容される担体と約4〜約20残基のペプチドとを含んで成る治療的に有効な投与 量の薬理組成物を投与することを含んで成り、ここでこのペプチドはDR座の実質 的に全てのアレルによりコードされるMHC分子上の抗原結合性部位に結合できる 、方法。 12.前記ペプチドが請求項1記載のペプチドである、請求項11記 載の方法。 13.前記ペプチドが請求項3記載のペプチドである、請求項11記載の方法。 14.患者のT細胞クローンの活性化を誘導する方法であって、この患者に、薬 理学的に許容される担体と約4〜約20残基のペプチドとを含んで成る治療的に有 効な投与量の薬理組成物を投与することを含んで成り、ここでこのペプチドはDR 座の実質的に全てのアレルによりコードされるMHC分子上の抗原結合性部位に結 合できる、方法。 15.前記ペプチドがCTL誘導性ペプチドに接合されている、請求項14記載の方 法。 16.前記ペプチドが請求項1記載のペプチドである、請求項14記載の方法。 17.前記ペプチドが請求項3記載のペプチドである、請求項14記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12110193A | 1993-09-14 | 1993-09-14 | |
US08/121,101 | 1993-09-14 | ||
PCT/US1994/010368 WO1995007707A1 (en) | 1993-09-14 | 1994-09-14 | Alteration of immune response using pan dr-binding peptides |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09505559A true JPH09505559A (ja) | 1997-06-03 |
JP3926839B2 JP3926839B2 (ja) | 2007-06-06 |
Family
ID=22394559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50932395A Expired - Lifetime JP3926839B2 (ja) | 1993-09-14 | 1994-09-14 | 万能dr−結合性ペプチドを用いる免疫応答の改変 |
Country Status (11)
Country | Link |
---|---|
US (2) | US5736142A (ja) |
EP (1) | EP0735893B1 (ja) |
JP (1) | JP3926839B2 (ja) |
CN (1) | CN1135181A (ja) |
AT (1) | ATE415173T1 (ja) |
AU (1) | AU698962B2 (ja) |
DE (1) | DE69435171D1 (ja) |
DK (1) | DK0735893T3 (ja) |
ES (1) | ES2318848T3 (ja) |
PT (1) | PT735893E (ja) |
WO (1) | WO1995007707A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003509465A (ja) * | 1999-07-19 | 2003-03-11 | エピミューン, インコーポレイテッド | ペプチドおよび核酸組成物を使用する、c型肝炎ウイルスに対する細胞性免疫応答の誘導 |
JP2006516639A (ja) * | 2003-02-01 | 2006-07-06 | ニユーララブ・リミテツド | 可溶性A−βに対する抗体を生成させるための能動免疫 |
JP2007277250A (ja) * | 2000-08-24 | 2007-10-25 | Univ California | アテローム性動脈硬化症を改善する経口投与ペプチド |
JP2011201902A (ja) * | 2011-05-19 | 2011-10-13 | Wyeth Llc | 可溶性A−βに対する抗体を生成させるための能動免疫 |
JP2012516140A (ja) * | 2009-01-28 | 2012-07-19 | エピミューン,インコーポレイティド | Pan−dr結合ポリペプチドおよびその使用 |
JP2012522802A (ja) * | 2009-04-01 | 2012-09-27 | ユニバーシティ オブ マイアミ | ワクチン組成物及びその使用方法 |
Families Citing this family (189)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110097352A9 (en) * | 1992-01-29 | 2011-04-28 | Pharmexa Inc. | Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions |
US7252829B1 (en) * | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
US7611713B2 (en) * | 1993-03-05 | 2009-11-03 | Pharmexa Inc. | Inducing cellular immune responses to hepatitis B virus using peptide compositions |
US9266930B1 (en) | 1993-03-05 | 2016-02-23 | Epimmune Inc. | Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions |
US20050049197A1 (en) * | 1993-09-14 | 2005-03-03 | Epimmune Inc. | Induction of immune response against desired determinants |
US6413935B1 (en) * | 1993-09-14 | 2002-07-02 | Epimmune Inc. | Induction of immune response against desired determinants |
ES2318848T3 (es) | 1993-09-14 | 2009-05-01 | Pharmexa Inc. | Peptidos que se unen a pan dr para potenciar la respuesta inmunitaria. |
AU3887495A (en) * | 1994-09-30 | 1996-04-26 | Anergen, Inc. | Preparation of mhc-peptide complexes |
GB9509844D0 (en) * | 1995-05-16 | 1995-07-12 | Cancer Res Campaign Tech | Screening for inhibitors of TCR-MHC interactions |
EP0876398B1 (en) * | 1996-01-24 | 2002-07-17 | Epimmune, Inc. | Induction of immune response against desired determinants |
GB9702377D0 (en) * | 1996-02-23 | 1997-03-26 | Zeneca Ltd | Peptide derivatives |
US20040171028A1 (en) * | 1996-06-06 | 2004-09-02 | Baker Brenda F. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
KR100451522B1 (ko) | 1996-06-07 | 2004-12-08 | 아스트라제네카 유케이 리미티드 | 펩티드유도체 |
JP4156671B2 (ja) * | 1996-06-11 | 2008-09-24 | ノーザン シドニー アンド セントラル コースト エリア ヘルス サービス | T細胞抗原受容体ペプチド |
GB9621836D0 (en) | 1996-10-19 | 1996-12-11 | Zeneca Ltd | Peptide compounds |
US6562345B1 (en) * | 1996-11-12 | 2003-05-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
GB9624562D0 (en) | 1996-11-27 | 1997-01-15 | Zeneca Ltd | Peptide derivatives |
US6413517B1 (en) | 1997-01-23 | 2002-07-02 | Epimmune, Inc. | Identification of broadly reactive DR restricted epitopes |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US7790856B2 (en) * | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US6787523B1 (en) * | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US20080050367A1 (en) * | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US6923964B1 (en) | 1997-12-02 | 2005-08-02 | Neuralab Limited | Active immunization of AScr for prion disorders |
US20050059802A1 (en) * | 1998-04-07 | 2005-03-17 | Neuralab Ltd | Prevention and treatment of amyloidogenic disease |
ES2371432T3 (es) * | 1998-05-13 | 2012-01-02 | Epimmune Inc. | Vectores de expresión para estimular una respuesta inmune y procedimientos de uso de los mismos. |
CA2685270C (en) * | 1998-05-13 | 2014-07-29 | Pharmexa Inc. | Expression vectors for stimulating an immune response and methods of using the same |
US20030147882A1 (en) * | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
EP2036573A1 (en) | 1998-06-17 | 2009-03-18 | IDM Pharma, Inc. | HLA binding peptides and their uses |
JP2003521448A (ja) | 1998-07-23 | 2003-07-15 | ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 合成ペプチドおよび自己免疫疾患治療のための使用方法 |
US6800730B1 (en) * | 1998-10-02 | 2004-10-05 | Ludwig Institute For Cancer Research | Isolated peptides which bind to MHC class II molecules, and uses thereof |
TR200100936T2 (tr) | 1998-10-05 | 2001-08-21 | Pharmexa A/S | Terapötik aşılama |
DK1117421T3 (da) * | 1998-10-05 | 2004-11-01 | Pharmexa As | Hidtil ukendte fremgangsmåder til terapuetisk vaccination |
EA200101125A1 (ru) | 1999-04-23 | 2002-04-25 | Фармекса А/С | Способ понижающей регуляции активности il5 |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) * | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
TR200400621T2 (tr) | 1999-07-20 | 2004-08-23 | Pharmexa A/S | GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem. |
JP4873810B2 (ja) * | 1999-10-05 | 2012-02-08 | エピミューン インコーポレイテッド | ペプチドおよび核酸組成物を使用する、ヒト免疫不全ウイルス−1に対する細胞性免疫応答の誘導 |
WO2001036452A2 (en) * | 1999-11-18 | 2001-05-25 | Epimmune Inc. | Heteroclitic analogs of class i epitodes |
AU784634B2 (en) | 1999-11-30 | 2006-05-18 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
US7026443B1 (en) * | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
US20040037843A1 (en) * | 1999-12-21 | 2004-02-26 | John Fikes | Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions |
US7462354B2 (en) * | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
DK1259251T3 (da) * | 2000-02-21 | 2006-03-06 | Pharmexa As | Hidtil ukendt fremgangsmåde til nedregulering af amyloid |
CZ20022748A3 (cs) * | 2000-02-21 | 2004-03-17 | Pharmexa A/S | Nová metoda regulace obsahu amyloidu |
US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
US6989146B2 (en) * | 2000-08-09 | 2006-01-24 | The Regents Of The University Of California | Stress proteins and peptides and methods of use thereof |
EP1652856A1 (en) * | 2000-08-09 | 2006-05-03 | The Regents of The University of California San Diego | Stress proteins-derived peptides and method of use thereof |
DE60135232D1 (de) | 2000-08-28 | 2008-09-18 | Agensys Inc | Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen |
EP1911461B1 (en) | 2000-10-19 | 2011-12-07 | Epimmune Inc. | HLA class I and II binding peptides and their uses |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
PE20020574A1 (es) * | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
US20040121946A9 (en) * | 2000-12-11 | 2004-06-24 | John Fikes | Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions |
US7097837B2 (en) | 2001-02-19 | 2006-08-29 | Pharmexa A/S | Synthetic vaccine agents |
US6924358B2 (en) | 2001-03-05 | 2005-08-02 | Agensys, Inc. | 121P1F1: a tissue specific protein highly expressed in various cancers |
US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
WO2002083921A2 (en) | 2001-04-10 | 2002-10-24 | Agensys, Inc. | Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers |
US20030191073A1 (en) | 2001-11-07 | 2003-10-09 | Challita-Eid Pia M. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
WO2002092120A1 (en) * | 2001-05-15 | 2002-11-21 | Ludwig Institute For Cancer Research | Structurally modified peptides and uses thereof |
MY144532A (en) * | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
CA2459318C (en) | 2001-09-06 | 2017-09-26 | Agensys, Inc. | Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer |
MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
JP2005535627A (ja) * | 2002-06-25 | 2005-11-24 | シティ・オブ・ホープ | アジュバント不含ペプチド・ワクチン |
AU2003243151A1 (en) | 2002-08-16 | 2004-03-03 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
US7432351B1 (en) | 2002-10-04 | 2008-10-07 | Mayo Foundation For Medical Education And Research | B7-H1 variants |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
WO2008103472A2 (en) | 2007-02-23 | 2008-08-28 | Elan Pharmaceuticals, Inc. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
JP2006508163A (ja) | 2002-11-27 | 2006-03-09 | アジェンシス, インコーポレイテッド | 癌の処置および検出において有用な24p4c12と称される、核酸および対応タンパク質 |
EP1903056A3 (en) | 2002-12-10 | 2008-05-07 | Idm Pharma, Inc. | HLA-A1, -A2 -A3, -A24, -B7, and -B44 binding peptides comprising tumor associated antigen epitopes, and compositions thereof |
CA2505870A1 (en) * | 2002-12-11 | 2004-06-24 | Soren Mouritsen | Targeting single epitopes |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
AU2004210975B2 (en) | 2003-02-10 | 2008-04-10 | Agensys, Inc. | Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers |
CA2520768A1 (en) * | 2003-03-28 | 2005-02-10 | Idm Pharma, Inc. | Methods of identifying optimal variants of peptide epitopes |
CA2522812C (en) | 2003-04-18 | 2012-08-21 | Idm Pharma, Inc. | Hla-a2 tumor associated antigen peptides and compositions |
US7622564B2 (en) | 2003-05-30 | 2009-11-24 | Agensys, Inc. | Prostate stem cell antigen (PSCA) variants and subsequences thereof |
TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
US9090673B2 (en) | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
MY144231A (en) | 2003-12-17 | 2011-08-15 | Wyeth Corp | Aß IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME |
UA93854C2 (ru) | 2003-12-17 | 2011-03-25 | Вайет Ллк | Иммуногенный конъюгат и способ его получения |
EP1753871B1 (en) | 2004-05-28 | 2015-07-15 | Agensys, Inc. | Antibodies and related molecules that bind to psca proteins |
CA2566506A1 (en) * | 2004-06-01 | 2005-12-15 | Innogenetics N.V. | Peptides for inducing a ctl and/or htl response to hepatitis c virus |
EP1781326A4 (en) * | 2004-06-04 | 2009-01-14 | Pharmexa Inc | INDUCTION OF AN IMMUNE RESPONSE AGAINST STREPTOCOKE PENUMONIA POLYSACCHARIDES |
EA013752B1 (ru) | 2004-08-09 | 2010-06-30 | Элан Фармасьютикалз, Инк. | Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний |
CA2943949C (en) | 2004-10-06 | 2020-03-31 | Mayo Foundation For Medical Education And Research | B7-h1 and methods of diagnosis, prognosis, and treatment of cancer |
AR052051A1 (es) | 2004-12-15 | 2007-02-28 | Neuralab Ltd | Anticuerpos ab humanizados usados en mejorar la cognicion |
PE20061401A1 (es) * | 2004-12-15 | 2006-12-23 | Neuralab Ltd | ANTICUERPOS Aß PARA MEJORAR LA COGNICION |
EP1838854B1 (en) * | 2004-12-15 | 2012-10-31 | Janssen Alzheimer Immunotherapy | Antibodies that recognize Beta Amyloid Peptide |
KR100646313B1 (ko) | 2004-12-31 | 2006-11-14 | 강원대학교산학협력단 | 알러지 질환 예방 및 치료용 펩티드 또는 그의 염 및 이를함유한 의약 조성물 |
EP1863848A4 (en) | 2005-03-31 | 2009-09-23 | Agensys Inc | CORRESPONDING ANTIBODIES AND MOLECULES THAT ATTACH PROTEINS 161P2F10B |
PT2289909E (pt) | 2005-11-30 | 2015-02-10 | Abbvie Inc | Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos |
RU2432362C2 (ru) | 2005-11-30 | 2011-10-27 | Эбботт Лэборетриз | Моноклональные антитела и их применения |
ES2310072B1 (es) | 2005-12-23 | 2009-11-16 | Proyecto De Biomedicina Cima, S.L. | Nuevos peptidos determinantes antigenicos t colaboradores (/dth). |
WO2010002478A2 (en) | 2008-07-03 | 2010-01-07 | University Of Georgia Research Foundation, Inc. | Glycopeptide and uses thereof |
CA2674269C (en) | 2006-01-03 | 2018-06-12 | University Of Georgia Research Foundation, Inc. | Three component glycolipopeptides |
EP2016095A2 (en) * | 2006-04-13 | 2009-01-21 | Peptimmune, Inc. | Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability |
US20090036653A1 (en) * | 2006-04-13 | 2009-02-05 | Peptimmune, Inc. | Methods for the directed expansion of epitopes for use as antibody ligands |
US8784810B2 (en) * | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
WO2008054540A2 (en) * | 2006-05-18 | 2008-05-08 | Pharmexa Inc. | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
WO2008042024A2 (en) | 2006-06-01 | 2008-04-10 | Elan Pharmaceuticals, Inc. | Neuroactive fragments of app |
PL2059256T3 (pl) | 2006-08-11 | 2017-02-28 | Life Sciences Research Partners Vzw | Immunogenne peptydy i ich zastosowanie w zaburzeniach immunologicznych |
EP2596801B1 (en) | 2006-10-06 | 2018-05-02 | Bavarian Nordic A/S | Recombinant modified vaccinia ankara virus encoding a her-2 antigen for use in treating cancer |
US20090142362A1 (en) * | 2006-11-06 | 2009-06-04 | Avant Immunotherapeutics, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP) |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
WO2008083169A2 (en) | 2006-12-26 | 2008-07-10 | The Johns Hopkins University | Compositions and methods for the treatment of immunologic disorders |
CA2673659A1 (en) * | 2006-12-27 | 2008-07-10 | The Johns Hopkins University | Methods of detecting and diagnosing inflamatory responses and disorders by determining the level of soluble b7-h4 |
US20090142342A1 (en) * | 2006-12-27 | 2009-06-04 | Johns Hopkins University | B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases |
US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
ES2570182T3 (es) | 2007-02-23 | 2016-05-17 | Prothena Biosciences Ltd | Prevención y tratamiento de la enfermedad sinucleinopática y amiloidogénica |
WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
WO2008121836A1 (en) * | 2007-03-30 | 2008-10-09 | Brigham And Women's Hospital, Inc. | Compounds and methods for enhancing mhc class ii therapies |
JP2011526240A (ja) * | 2007-04-18 | 2011-10-06 | ヤンセン アルツハイマー イミュノセラピー | 脳アミロイド血管症の予防および治療 |
US8003097B2 (en) * | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
CA2686817A1 (en) * | 2007-05-07 | 2009-02-19 | Peptimmune, Inc. | Methods for the directed expansion of epitopes for use as antibody ligands |
ES2498040T3 (es) | 2007-07-27 | 2014-09-24 | Janssen Alzheimer Immunotherapy | Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados |
AP3467A (en) * | 2007-10-16 | 2015-11-30 | Peptimmune Inc | Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes |
JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
US20100310640A1 (en) * | 2007-11-01 | 2010-12-09 | Knutson Keith L | Hla-dr binding peptides and their uses |
US20090169549A1 (en) * | 2007-12-19 | 2009-07-02 | The Board Of Regents Of The University Of Texas System | Conformational isomers of alpha-synuclein, antibodies thereto and methods of their manufacture and use |
EP2730659A3 (en) | 2007-12-28 | 2016-01-13 | Prothena Biosciences Limited | Treatment and Prophylaxis of Amyloidosis |
ES2676630T3 (es) | 2008-02-14 | 2018-07-23 | Life Sciences Research Partners Vzw | Control inmunogénico de tumores y células tumorales |
EP2278998A1 (en) * | 2008-04-17 | 2011-02-02 | Declion Pharmaceuticals, Inc. | Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
WO2010088393A2 (en) * | 2009-01-28 | 2010-08-05 | Antigen Express, Inc. | Li-kay hybrid peptides that modulate the immune response to influenza |
EP3611270B1 (en) | 2009-05-19 | 2021-12-01 | University Of Miami | Kits for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs |
CN102666581A (zh) | 2009-08-31 | 2012-09-12 | 艾普利穆恩公司 | 用于抑制移植物排斥的方法和组合物 |
JP5955771B2 (ja) | 2009-10-22 | 2016-07-20 | トーマス・ジェファーソン・ユニバーシティThomas Jefferson University | 細胞ベースの抗癌組成物ならびに当該物の製造方法および使用方法 |
ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
CA2798493A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Synthetic nanocarrier combination vaccines |
CA2808187A1 (en) | 2010-08-14 | 2012-02-23 | Abbvie Inc. | Amyloid-beta binding proteins |
EP2646459B1 (en) | 2010-12-02 | 2020-01-08 | Bionor Immuno AS | Peptide scaffold design |
CA2821995C (en) | 2011-01-06 | 2019-02-12 | Bionor Immuno As | Monomeric and multimeric peptides immunogenic against hiv |
KR20140050698A (ko) | 2011-07-29 | 2014-04-29 | 셀렉타 바이오사이언시즈, 인크. | 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체 |
AU2012323189A1 (en) | 2011-10-12 | 2014-03-06 | Alpha-O Peptides Ag | Self-assembling peptide nanoparticles as vaccines against infection with norovirus |
GB201201511D0 (en) * | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
IN2014KN02769A (ja) | 2012-06-06 | 2015-05-08 | Bionor Immuno As | |
AU2013331328B2 (en) | 2012-10-19 | 2018-05-31 | Bavarian Nordic A/S | Methods and compositions for the treatment of cancer |
SG10201707855YA (en) | 2013-03-13 | 2017-10-30 | Prothena Biosciences Ltd | Tau immunotherapy |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
WO2015017734A1 (en) | 2013-07-31 | 2015-02-05 | Board Of Trustees Of The University Of Arkansas | Compositions for and methods of treating and preventing cancer targeting tumor associated carbohydrate antigens |
ES2714708T3 (es) | 2013-10-01 | 2019-05-29 | Mayo Found Medical Education & Res | Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim |
JP2017501848A (ja) | 2013-11-19 | 2017-01-19 | プロセナ バイオサイエンシーズ リミテッド | 便秘症状からのレビー小体病の免疫療法のモニター |
WO2015175340A1 (en) | 2014-05-13 | 2015-11-19 | Bavarian Nordic, Inc. | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3 |
KR20170003912A (ko) | 2014-03-19 | 2017-01-10 | 매카이 메디컬 파운데이션 더 프레즈비티리언 처치 인 타이완 매카이 메모리얼 호스피탈 | 면역원성 당펩타이드에 대한 항체, 이를 포함하는 조성물 및 이의 용도 |
WO2015164798A1 (en) | 2014-04-25 | 2015-10-29 | Tria Bioscience Corp. | Synthetic hapten carrier compositions and methods |
WO2015179654A1 (en) | 2014-05-22 | 2015-11-26 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti b7-h1 antibodies |
US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
GB201418433D0 (en) | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
US10441644B2 (en) | 2015-05-05 | 2019-10-15 | The Regents Of The University Of California | H3.3 CTL peptides and uses thereof |
AU2016258984B2 (en) | 2015-05-05 | 2020-11-19 | The Regents Of The University Of California | H3.3 CTL peptides and uses thereof |
US10729791B2 (en) | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
KR102571745B1 (ko) | 2015-06-29 | 2023-08-25 | 오제 이뮈노테라프틱스 | 짧은 펩타이드 항-암 백신을 이용하여 초기 t 기억 반응을 유도하는 방법 |
WO2017075045A2 (en) | 2015-10-30 | 2017-05-04 | Mayo Foundation For Medical Education And Research | Antibodies to b7-h1 |
US10889638B2 (en) | 2016-05-02 | 2021-01-12 | Prothena Biosciences Limited | Antibodies recognizing tau |
JP7170316B2 (ja) | 2016-05-02 | 2022-11-14 | プロセナ バイオサイエンシーズ リミテッド | タウ免疫療法 |
IL299962A (en) | 2016-05-02 | 2023-03-01 | Scripps Research Inst | Compositions and methods related to HIV-1 immunogens |
MY197413A (en) | 2016-05-02 | 2023-06-16 | Prothena Biosciences Ltd | Antibodies recognizing tau |
EP3606550A2 (en) | 2017-04-03 | 2020-02-12 | Neon Therapeutics, Inc. | Protein antigens and uses thereof |
BR112019022906A2 (pt) | 2017-05-02 | 2020-05-26 | Prothena Biosciences Limited | Anticorpos que reconhecem tau |
PE20191842A1 (es) | 2017-05-08 | 2019-12-31 | Gritstone Oncology Inc | Vectores de neoantigeno de alfavirus |
WO2018213803A1 (en) | 2017-05-19 | 2018-11-22 | Neon Therapeutics, Inc. | Immunogenic neoantigen identification |
EP3648791A1 (en) | 2017-07-04 | 2020-05-13 | CureVac AG | Novel nucleic acid molecules |
US10780178B2 (en) | 2017-11-01 | 2020-09-22 | The Scripps Research Institute | Scaffolded HIV-1 vaccine immunogens |
US11696936B2 (en) | 2017-11-27 | 2023-07-11 | Ose Immunotherapeutics | Treatment of cancer |
EP3735271A4 (en) | 2018-01-04 | 2022-06-15 | Iconic Therapeutics, Inc. | ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY DRUG CONJUGATES AND RELATED METHODS |
CN109748952B (zh) * | 2018-05-02 | 2020-09-15 | 中国药科大学 | 辅助性表位肽及其应用 |
CN112469661B (zh) | 2018-06-13 | 2024-04-26 | 斯克里普斯研究学院 | 具有新结构组分的纳米粒疫苗 |
WO2020070303A1 (en) | 2018-10-05 | 2020-04-09 | Bavarian Nordic A/S | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist |
MX2021005560A (es) | 2018-11-20 | 2021-06-23 | Bavarian Nordic As | Terapia para el tratamiento del cancer con administracion intratumoral y/o intravenosa de un virus vaccinia ankara (mva) recombinante que codifica ligando 4-1bbl (cd137l) y/o ligando del cumulo o grupo de diferenciacion 40 (cd40l). |
TW202039534A (zh) | 2018-12-14 | 2020-11-01 | 美商美國禮來大藥廠 | KRAS變體mRNA分子 |
AU2020207087A1 (en) | 2019-01-12 | 2021-08-12 | The Methodist Hospital | Self-assembled peptide nanoparticle and use thereof |
EP3935083A4 (en) | 2019-03-03 | 2022-11-30 | Prothena Biosciences Limited | ANTIBODIES RECOGNIZING TAU PROTEIN |
TW202110870A (zh) | 2019-05-30 | 2021-03-16 | 美商葛利史東腫瘤科技公司 | 經修飾之腺病毒 |
JP2023503857A (ja) | 2019-11-20 | 2023-02-01 | バヴァリアン・ノルディック・アクティーゼルスカブ | がんを治療するための腫瘍内及び/または静脈内投与用組み換えmvaウイルス |
US20220409732A1 (en) | 2019-12-02 | 2022-12-29 | Regeneron Pharmaceuticals, Inc. | Peptide-mhc ii protein constructs and uses thereof |
EP4149531A1 (en) | 2020-05-11 | 2023-03-22 | Ose Immunotherapeutics | Vaccine against sars-cov virus |
TW202208409A (zh) | 2020-05-19 | 2022-03-01 | 愛爾蘭商歐薩爾普羅席納有限公司 | 用於治療阿茲海默症之多抗原決定基疫苗 |
BR112022026508A2 (pt) | 2020-06-24 | 2023-03-07 | Prothena Biosciences Ltd | Anticorpos que reconhecem sortilina |
CN116438308A (zh) | 2020-08-06 | 2023-07-14 | 磨石生物公司 | 多表位疫苗盒 |
WO2022268916A2 (en) | 2021-06-23 | 2022-12-29 | Ose Immunotherapeutics | Pan-coronavirus peptide vaccine |
WO2023118508A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5785973A (en) | 1988-02-01 | 1998-07-28 | Praxis Biologics, Inc. | Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines |
GB8812214D0 (en) * | 1988-05-24 | 1988-06-29 | Hoffmann La Roche | Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope |
IT1237764B (it) * | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
US5336758A (en) * | 1990-03-09 | 1994-08-09 | The United States Of America As Represented By The Department Of Health And Human Services | Peptides stimulating cytotoxic T cells immune to HIV RT |
WO1992002543A1 (en) * | 1990-08-01 | 1992-02-20 | Cytel Corporation | Novel immunosuppressant peptides |
US5679640A (en) | 1991-02-12 | 1997-10-21 | Cytel Corporation | Immunosuppressant peptides |
WO1993003764A1 (en) * | 1991-08-26 | 1993-03-04 | Cytel Corporation | Hla-restricted hepatitis b virus ctl epitopes |
WO1993005011A1 (en) * | 1991-08-29 | 1993-03-18 | Sandoz Ltd. | Novel immunosuppressants |
WO1994020127A1 (en) | 1993-03-05 | 1994-09-15 | Cytel Corporation | Hla-a2.1 binding peptides and their uses |
ES2318848T3 (es) | 1993-09-14 | 2009-05-01 | Pharmexa Inc. | Peptidos que se unen a pan dr para potenciar la respuesta inmunitaria. |
CA2685270C (en) * | 1998-05-13 | 2014-07-29 | Pharmexa Inc. | Expression vectors for stimulating an immune response and methods of using the same |
-
1994
- 1994-09-14 ES ES94929801T patent/ES2318848T3/es not_active Expired - Lifetime
- 1994-09-14 US US08/305,871 patent/US5736142A/en not_active Expired - Lifetime
- 1994-09-14 AT AT94929801T patent/ATE415173T1/de active
- 1994-09-14 JP JP50932395A patent/JP3926839B2/ja not_active Expired - Lifetime
- 1994-09-14 CN CN94194128A patent/CN1135181A/zh active Pending
- 1994-09-14 EP EP94929801A patent/EP0735893B1/en not_active Expired - Lifetime
- 1994-09-14 DE DE69435171T patent/DE69435171D1/de not_active Expired - Lifetime
- 1994-09-14 PT PT94929801T patent/PT735893E/pt unknown
- 1994-09-14 AU AU78736/94A patent/AU698962B2/en not_active Ceased
- 1994-09-14 DK DK94929801T patent/DK0735893T3/da active
- 1994-09-14 WO PCT/US1994/010368 patent/WO1995007707A1/en active Application Filing
-
2000
- 2000-11-08 US US09/709,774 patent/US7202351B1/en not_active Expired - Fee Related
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003509465A (ja) * | 1999-07-19 | 2003-03-11 | エピミューン, インコーポレイテッド | ペプチドおよび核酸組成物を使用する、c型肝炎ウイルスに対する細胞性免疫応答の誘導 |
JP2007277250A (ja) * | 2000-08-24 | 2007-10-25 | Univ California | アテローム性動脈硬化症を改善する経口投与ペプチド |
JP2010280718A (ja) * | 2000-08-24 | 2010-12-16 | Regents Of The Univ Of California | アテローム性動脈硬化症を改善する経口投与ペプチド |
JP2006516639A (ja) * | 2003-02-01 | 2006-07-06 | ニユーララブ・リミテツド | 可溶性A−βに対する抗体を生成させるための能動免疫 |
JP2012516140A (ja) * | 2009-01-28 | 2012-07-19 | エピミューン,インコーポレイティド | Pan−dr結合ポリペプチドおよびその使用 |
JP2012522802A (ja) * | 2009-04-01 | 2012-09-27 | ユニバーシティ オブ マイアミ | ワクチン組成物及びその使用方法 |
JP2015096520A (ja) * | 2009-04-01 | 2015-05-21 | ユニバーシティ オブ マイアミ | ワクチン組成物及びその使用方法 |
JP2016188222A (ja) * | 2009-04-01 | 2016-11-04 | ユニバーシティ オブ マイアミ | ワクチン組成物及びその使用方法 |
US9764012B2 (en) | 2009-04-01 | 2017-09-19 | University Of Miami | Vaccine compositions and methods of use thereof |
JP2017165755A (ja) * | 2009-04-01 | 2017-09-21 | ユニバーシティ オブ マイアミ | ワクチン組成物及びその使用方法 |
JP2011201902A (ja) * | 2011-05-19 | 2011-10-13 | Wyeth Llc | 可溶性A−βに対する抗体を生成させるための能動免疫 |
Also Published As
Publication number | Publication date |
---|---|
JP3926839B2 (ja) | 2007-06-06 |
EP0735893A1 (en) | 1996-10-09 |
CN1135181A (zh) | 1996-11-06 |
EP0735893A4 (en) | 1998-02-04 |
ATE415173T1 (de) | 2008-12-15 |
WO1995007707A1 (en) | 1995-03-23 |
PT735893E (pt) | 2009-03-06 |
DK0735893T3 (da) | 2009-03-09 |
EP0735893B1 (en) | 2008-11-26 |
ES2318848T3 (es) | 2009-05-01 |
AU7873694A (en) | 1995-04-03 |
AU698962B2 (en) | 1998-11-12 |
US7202351B1 (en) | 2007-04-10 |
US5736142A (en) | 1998-04-07 |
DE69435171D1 (de) | 2009-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3926839B2 (ja) | 万能dr−結合性ペプチドを用いる免疫応答の改変 | |
JP3908271B2 (ja) | Hla−a2.1結合ペプチドおよびそれらの使用 | |
JP3586278B2 (ja) | Hla−制限型b型肝炎ウィルスのctlエピトープ | |
JP4210734B2 (ja) | Hla結合ペプチド及びその使用 | |
US20020160019A1 (en) | Identification of broadly reactive DR restricted epitopes | |
JP3650110B2 (ja) | B型肝炎ウイルスに対する細胞毒性tリンパ球応答を誘発するためのペプチド | |
JP2002507397A (ja) | Hla結合ペプチド及びその使用 | |
JP2001504799A (ja) | Hla分子への結合アフィニティーが増加したペプチド | |
JP2003535024A (ja) | Hla結合ペプチドおよびそれらの使用 | |
JP2002515869A (ja) | Hla―a2.1結合ペプチド及びその使用 | |
Romero et al. | Immunization with synthetic peptides containing a defined malaria epitope induces a highly diverse cytotoxic T lymphocyte response. Evidence that two peptide residues are buried in the MHC molecule. | |
JP3657603B2 (ja) | B型肝炎のウイルスに対する細胞障害性tリンパ球の応答を誘発するペプチド | |
JPH10503493A (ja) | Hla 結合性ペプチド及びそれらの使用 | |
JP4063879B2 (ja) | 所望の決定基に対する免疫応答の誘導 | |
JP2003524016A (ja) | Hla結合ペプチドおよびそれらの用途 | |
US20050049197A1 (en) | Induction of immune response against desired determinants | |
JP2002518346A (ja) | Hla結合ペプチドおよびそれらの用途 | |
JP2004517609A (ja) | Hla−a2.1結合ペプチドおよびそれらの用途 | |
US20150203830A1 (en) | Compositions comprising nucleic acids encoding hiv-1 reverse transcriptase ctl epitopes | |
WO1992021377A1 (en) | Peptides for use in induction of t cell activation against hiv-1 | |
JP2004508340A (ja) | Hla結合ペプチドおよびその使用方法 | |
MXPA98007512A (en) | Peptides with increased affinity by molecules from locus to leucocitus huma | |
JP2010001303A (ja) | Hla結合ペプチド及びその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051011 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060110 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060411 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060711 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061010 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061106 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061127 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070130 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070301 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100309 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110309 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110309 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120309 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130309 Year of fee payment: 6 |